- BioMerieux reported 1Q Sales of EU965.2M, which is a significant increase from the previous year’s EU905.7M.
- The sales figure represents an increase of +6.6% year on year.
- Organic sales have also shown a remarkable growth of +9.8%.
- The company’s year forecast still projects an increase in organic sales of between +6% to +8%.
- BioMerieux predicts that its 2024 contributive operating income before non-recurring items will grow by at least +10% at constant exchange rates.
- The company held its Capital Markets Day on April 9.
- The firm has been given a strong vote of confidence by market analysts, with 10 buying recommendations, 3 holds, and 0 sells.
A look at BioMerieux Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
BioMerieux, a company that focuses on in vitro diagnostics for medical and industrial purposes, has a promising long-term outlook according to Smartkarma’s Smart Scores. With a score of 4 in resilience, the company shows strong potential for weathering economic and market challenges. Additionally, BioMerieux scores a 3 in both growth and momentum, indicating potential for future expansion and positive market performance. While the scores for value and dividend are slightly lower at 2, this does not detract from the overall positive outlook for the company. BioMerieux‘s expertise in infectious disease diagnosis and analysis of food and pharmaceutical samples positions them well in the market, making them a company to watch in the long-term.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
